 |
市場調查報告書
商品編碼
1550545
抗憂鬱症市場：按藥物類別、給藥途徑、分銷管道和地區分類Antidepressant Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
預計2024年全球抗憂鬱症市場規模為187.2億美元，預計2031年將達305億美元，2024年至2031年年複合成長率(CAGR)為7.2%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年 | 2023年 | 2024年市場規模 | 187.2億美元 |
| 實際資料 | 2019年至2023年 | 預測期 | 從2024年到2031年 |
| 預測 2024-2031 年複合年成長率： | 7.20% | 2031年價值預測 | 305億美元 |
抗憂鬱症是治療重度憂鬱症的藥物。它用於改變大腦化學物質，以緩解悲傷、興趣喪失、內疚感和自我價值感低下、睡眠障礙和食慾不振、疲勞和注意力不集中等症狀。憂鬱症和其他精神疾病的盛行率和認知不斷提高，推動了全球對抗抗憂鬱症的需求。此外，大型製藥企業開拓新的先進治療方法也正在推動市場成長。然而，替代治療方法的可用性以及與抗憂鬱症相關的副作用在一定程度上限制了市場的擴張。
市場動態：
影響全球抗憂鬱症市場成長的市場促進因素包括憂鬱症和其他精神疾病盛行率的上升、對憂鬱症診斷和管理的認知不斷提高、新產品的推出以及醫療保健需求的增加，其中包括支出的增加。根據世界衛生組織估計，全球有超過 2.64 億人患有憂鬱症。根據失能壽命 (YLD) 來衡量，憂鬱症也是導致殘疾的主要原因。此外，抗憂鬱症治療憂鬱症以外的疾病，如焦慮症、創傷後壓力症候群（PTSD）、月經焦慮症（PMDD）和慢性疼痛的接受度不斷提高，也是推動市場成長的動力。然而，心理治療、電痙攣治療和社會支持等替代治療方法的可用性限制了全世界對抗抗憂鬱症的完全依賴。此外，隨著抗憂鬱症的使用，許多人會出現輕微到嚴重的副作用，例如失眠、性功能障礙、體重變化、胃腸道紊亂和頭痛，這限制了依從性和整體市場收益。新型抗憂鬱症的高成本也阻礙了市場開拓，特別是在價格敏感的開發中國家。學名藥開發為解決預算有限的消費者未滿足的需求提供了機會。
本研究的主要特點
本報告對全球抗憂鬱症市場進行了詳細分析，並呈現了以2023年為基準年的預測期（2024-2031年）的市場規模和年均成長率。
它還揭示了各個細分市場的潛在商機，並解釋了該市場中有吸引力的投資提案的矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
它根據公司亮點、產品系列、主要亮點、財務表現和策略等參數，介紹了全球抗憂鬱症藥物市場的主要企業的概況。
本研究涵蓋的主要企業包括輝瑞、禮來、阿斯特捷利康、葛蘭素史克和諾華。
該報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
全球抗憂鬱症市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過用於分析全球抗憂鬱症市場的各種策略矩陣來促進他們的決策。
目錄
第1章 研究目的與前提
- 研究目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章市場動態、法規及趨勢分析
- 市場動態
- 促進因素
- 抑制因素
- 機會
- 影響分析
- 市場趨勢
- 主要進展
- 監管場景
- 收購和合作場景
- 資金籌措和投資
- PEST分析
- 波特的分析
第4章全球抗憂鬱症市場 - 冠狀病毒 (COVID-19) 大流行的影響
- 整體影響
- 政府舉措
- COVID-19 對市場的影響
第5章全球抗憂鬱症市場，依藥物類別，2019-2031
- 選擇性血清素再回收抑制劑（SSRI）
- Fluoxetine
- 舍曲林
- 其他
- 正腎上腺素再回收抑制劑(SNRI)
- 文拉法辛
- Duloxetine
- 其他
- 三環抗憂鬱藥物（TCA）
- 阿米替林
- 丙咪嗪
- 其他
- 單胺氧化酵素抑制劑 (MAOIs)
- 苯乙肼
- 反苯環丙明
- 其他
- 非典型抗憂鬱症
- 安非他酮
- 曲唑酮
- 其他
第6章全球抗憂鬱症市場，依給藥途徑，2019-2031
- 口服
- 皮下的
- 靜脈
- 其他
第7章全球抗憂鬱症市場，依通路，2019-2031
- 醫院藥房
- 零售藥房
- 網路藥房
第8章全球抗憂鬱症市場，按地區，2019-2031
- 拉丁美洲
- 歐洲
- 亞太地區
- 中東
第9章 競爭格局
- 公司簡介
- Eli Lilly and Company
- Pfizer Inc.
- GlaxoSmithKline PLC
- AstraZeneca
- AbbVie Inc.
- Johnson &Johnson
- H. Lundbeck AS
- Sanofi
- Bristol-Myers Squibb
- Alkermes Plc
- F. Hoffmann-La Roche Ltd
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Neurocrine Biosciences, Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Indivior PLC
- Aurobindo Pharma
第10章分析師建議
- 命運之輪
- 分析師觀點
- 一致的機會圖
第11章調查方法
- 參考
- 調查方法
The Global Antidepressant Market is estimated to be valued at USD 18.72 Bn in 2024 and is expected to reach USD 30.50 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.2% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 18.72 Bn |
| Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
| Forecast Period 2024 to 2031 CAGR: | 7.20% | 2031 Value Projection: | US$ 30.50 Bn |
Antidepressants are medications prescribed to treat major depressive disorders. They are used to alter brain chemistry in order to relieve symptoms such as sadness, loss of interest, feelings of guilt or low self-worth, disturbed sleep or appetite, fatigue, and poor concentration. The increasing prevalence of depression and other mental health disorders along with growing awareness is fueling the demand for antidepressants globally. Moreover, development of new and advanced treatment options by major pharmaceutical companies is also boosting market growth. However, availability of alternative treatment methods and side-effects associated with antidepressant drugs restrict the market expansion to some extent.
Market Dynamics:
The drivers influencing growth of global antidepressant market include rising incidence of depression and other mental health conditions, growing awareness about depression diagnosis and management, new product launches, and increasing expenditure on healthcare. According to WHO, over 264 million people are estimated to suffer from depression worldwide. Depression is also the leading cause of disability as measured by Years Lived with Disability (YLDs). Furthermore, growing acceptance of antidepressants for conditions other than depression such as anxiety disorders, post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), and chronic pain is driving their market growth. However, availability of alternative treatment methods such as psychotherapy, electroconvulsive therapy, and social support is restricting complete reliance on antidepressants globally. Also, many individuals experience mild to serious side-effects such as insomnia, sexual dysfunction, weight changes, gastrointestinal issues, and headaches with antidepressant use, which limits their compliance and overall market revenue. High costs of new antidepressants also hinder the market growth, especially in price-sensitive developing nations. Development of generics offers opportunities to address the unmet needs of consumers with budget constraints.
Key features of the study:
This report provides in-depth analysis of the global antidepressant market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 s the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antidepressant market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer, Eli Lilly, AstraZeneca, GlaxoSmithKline, and Novartis
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global antidepressant market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antidepressant market
Detailed Segmentation-
- By Drug Class
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Fluoxetine
- Sertraline
- Others
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- Venlafaxine
- Duloxetine
- Others
- Tricyclic Antidepressants (TCAs)
- Amitriptyline
- Imipramine
- Others
- Monoamine Oxidase Inhibitors (MAOIs)
- Phenelzine
- Tranylcypromine
- Others
- Atypical Antidepressants
- Bupropion
- Trazodone
- Others
- By Route of Administration
- Oral
- Subcutaneous
- Intravenous
- Others
- By Distribution Channel
- Hospitals Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Eli Lilly and Company
- Pfizer Inc.
- GlaxoSmithKline PLC
- AstraZeneca
- AbbVie Inc.
- Johnson & Johnson
- Lundbeck AS
- Sanofi
- Bristol-Myers Squibb
- Alkermes Plc
- F. Hoffmann-La Roche Ltd
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Neurocrine Biosciences, Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Indivior PLC
- Aurobindo Pharma
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Antidepressant Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global Antidepressant Market, By Drug Class, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Fluoxetine
- Sertraline
- Others
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Venlafaxine
- Duloxetine
- Others
- Tricyclic Antidepressants (TCAs)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Amitriptyline
- Imipramine
- Others
- Monoamine Oxidase Inhibitors (MAOIs)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Phenelzine
- Tranylcypromine
- Others
- Atypical Antidepressants
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Bupropion
- Trazodone
- Others
6. Global Antidepressant Market, By Route of Administration, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Subcutaneous
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Intravenous
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Global Antidepressant Market, By Distribution Channel, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospitals Pharmacy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Retail Pharmacy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Online Pharmacy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
8. Global Antidepressant Market, By Region, 2019 - 2031, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2031
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Eli Lilly and Company
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GlaxoSmithKline PLC
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AbbVie Inc.
- Johnson & Johnson
- H. Lundbeck AS
- Sanofi
- Bristol-Myers Squibb
- Alkermes Plc
- F. Hoffmann-La Roche Ltd
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Neurocrine Biosciences, Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Indivior PLC
- Aurobindo Pharma
- Eli Lilly and Company
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. Research Methodology
- References
- Research Methodology
- About us and Sales Contact
